Ramucirumab + Paclitaxel (Second-line)
Treatment for Stomach Cancer
Typical Dosage: Ramucirumab: 8 mg/kg IV on days 1 and 15 of a 28-day cycle, Paclitaxel: 80 mg/m2 IV on days 1, 8, and 15 of a 28-day cycle
Effectiveness
65%
Safety Score
30%
Clinical Trials
16
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
Ramucirumab: 8 mg/kg IV on days 1 and 15 of a 28-day cycle, Paclitaxel: 80 mg/m2 IV on days 1, 8, and 15 of a 28-day cycle
Time to Effect
4-8 weeks
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
14(Treat 14 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
10(Treat 10 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120,000
Monitoring:$10,000
Side Effect Mgmt:$8,000
Total Annual:$138,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$350,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$492,857
Cost per Remission
$6,900,000
Comparison vs Paclitaxel alone
Cost Difference
+$80,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Ramucirumab + Paclitaxel (Second-line) Outcomes
for Stomach Cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+28%
Remission Rate
+2%
Common Side Effects
Neutropenia (Paclitaxel)
+40%
Hypertension
+15%
Fatigue
+40%
Peripheral neuropathy (Paclitaxel)
+30%
Hemorrhage
+10%
Active Clinical Trials
8 active trials recruiting for Ramucirumab + Paclitaxel (Second-line) in Stomach Cancer
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
NCT03760822ACTIVE NOT RECRUITINGPHASE2
112 participants
INTERVENTIONAL
Abbeville, France +37 more
Started: Nov 16, 2018
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer
NCT06490159RECRUITING
150 participants
OBSERVATIONAL
Kurashiki, Japan
Started: Oct 1, 2018
Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer
NCT06904300NOT YET RECRUITINGPHASE2
110 participants
INTERVENTIONAL
Started: Aug 15, 2025
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392RECRUITINGPHASE3
572 participants
INTERVENTIONAL
Birmingham, United States +185 more
Started: Mar 4, 2024
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases
NCT06675136RECRUITINGPHASE1
30 participants
INTERVENTIONAL
Duarte, United States
Started: Oct 29, 2025
Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer
NCT06962137RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Antwerp, Belgium +5 more
Started: Dec 11, 2025
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600RECRUITINGPHASE2, PHASE3
224 participants
INTERVENTIONAL
Little Rock, United States +362 more
Started: Jun 24, 2024
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
NCT05365581RECRUITINGPHASE1
398 participants
INTERVENTIONAL
Orange, United States +43 more
Started: Jun 7, 2022
Completed Clinical Trials
4 completed trials for Ramucirumab + Paclitaxel (Second-line) in Stomach Cancer
Predicting the Efficacy in Advanced Gastric Cancer.
NCT06490055COMPLETED
162 participants
OBSERVATIONAL
Monrovia, United States +1 more
Started: Oct 1, 2018
Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer
NCT06666582COMPLETED
185 participants
OBSERVATIONAL
Athens, Greece
Started: Mar 1, 2015
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
NCT02514551COMPLETEDPHASE2
245 participants
INTERVENTIONAL
Duarte, United States +51 more
Started: Oct 12, 2015
A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
NCT02898077COMPLETEDPHASE3
440 participants
INTERVENTIONAL
Beijing, China +31 more
Started: Mar 2, 2017